KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Common Equity (2018 - 2025)

Historic Common Equity for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $467.0 million.

  • Castle Biosciences' Common Equity rose 589.29% to $467.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $467.0 million, marking a year-over-year increase of 589.29%. This contributed to the annual value of $455.8 million for FY2024, which is 1650.17% up from last year.
  • Per Castle Biosciences' latest filing, its Common Equity stood at $467.0 million for Q3 2025, which was up 589.29% from $455.4 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Common Equity registered a high of $467.0 million during Q3 2025, and its lowest value of $378.8 million during Q2 2023.
  • Over the past 5 years, Castle Biosciences' median Common Equity value was $411.7 million (recorded in 2021), while the average stood at $416.6 million.
  • As far as peak fluctuations go, Castle Biosciences' Common Equity skyrocketed by 37602.41% in 2021, and later tumbled by 1017.22% in 2023.
  • Quarter analysis of 5 years shows Castle Biosciences' Common Equity stood at $411.7 million in 2021, then dropped by 3.06% to $399.2 million in 2022, then fell by 1.97% to $391.3 million in 2023, then grew by 16.5% to $455.8 million in 2024, then increased by 2.46% to $467.0 million in 2025.
  • Its last three reported values are $467.0 million in Q3 2025, $455.4 million for Q2 2025, and $440.3 million during Q1 2025.